CN112939892A - Preparation method of quetiapine - Google Patents
Preparation method of quetiapine Download PDFInfo
- Publication number
- CN112939892A CN112939892A CN202110308560.3A CN202110308560A CN112939892A CN 112939892 A CN112939892 A CN 112939892A CN 202110308560 A CN202110308560 A CN 202110308560A CN 112939892 A CN112939892 A CN 112939892A
- Authority
- CN
- China
- Prior art keywords
- quetiapine
- preparation
- sulphur nitrogen
- ethyl acetate
- dibenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The invention discloses a method for synthesizing quetiapine by using a ruthenium catalyst. With 11-piperazinyl dibenzo [ b, f][1,4]Sulphur nitrogen
Reacting with diethylene glycol as raw material under the catalysis of ruthenium catalyst to obtain 11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
Description
(I) technical field
The invention belongs to the technical field of medicines, and particularly relates to an antipsychotic drug quetiapine (11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl)]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
) The preparation method of (1).
(II) background of the invention
Quetiapine hemifumarate (quetiapine hemifumarate), common name: en ruikang, qi wei, english common name: quetiapine, chemical name is 11- [4- [2- (2-hydroxyethoxy) ethyl]-1-piperazinyl]Dibenzo [ b, f ]][1,4]Nitrogen sulfur
Hemifumarate, developed by AstraZeneca, UK, was approved by the United states FDA for marketing in 1997, which was first marketed in the United kingdom in the same year. The domestic quetiapine produced in 2000 is approved to be on the market, and the quetiapine imported in the same year is also registered in China and is on the market in the next year, and the quetiapine is an atypical antipsychotic, can block various neurotransmitter receptors such as dopamine and 5-hydroxytryptamine in brain, has stronger antipsychotic effect, and compared with other antipsychotic medicaments, the quetiapine has the characteristics of higher receptor selectivity, no adverse reaction of an extravertebral system, good oral absorption and complete metabolism, and is a first-line medicament for clinically treating schizophrenia.
Quetiapine hemifumarate has the structural formula:
11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
Is a precursor for the synthesis of quetiapine hemifumarate, which is usually made of 11-piperazinyldibenzo [ b, f][1,4]Sulphur nitrogen
Reacting with 2- (2-chloroethoxy) ethanol. This method has the following disadvantages: the method of using halogenated hydrocarbon to substitute the structural C-N bond has the advantages of easy reaction, low yield, large amount of undesirable waste and high production cost.
Disclosure of the invention
In order to overcome the defects of low yield, more byproducts and high cost in the prior art, the invention provides quetiapine (11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl)]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
) The preparation method of (1). The method has mild reaction conditions, high atom utilization rate, high product yield, low cost and only water as byproductAnd is environment-friendly and suitable for industrial production.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a preparation method of quetiapine, which comprises the following steps:
with 11-piperazinyl dibenzo [ b, f][1,4]Sulphur nitrogen
Reacting with diethylene glycol serving as a raw material in a ruthenium catalyst and an organic solvent at 120-160 ℃ (preferably 140 ℃) for 3-10 h (preferably 5h), and carrying out aftertreatment on the obtained reaction liquid to obtain the quetiapine (11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl)]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
) (ii) a The ruthenium catalyst, diethylene glycol and 11-piperazinyl dibenzo [ b, f ]][1,4]Sulphur nitrogen
The amount ratio of the substances (A) is 0.02 to 0.05: 1-5: 1, preferably 0.03: 3: 1; the ruthenium catalyst is bis (triphenylphosphine) carbonyl acetonitrile ruthenium dichloride, bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate or tetrakis (triphenylphosphine) ruthenium dichloride, preferably bis (triphenylphosphine) carbonyl acetonitrile ruthenium dichloride.
The reaction equation is as follows:
preferably, the organic solvent is selected from any one of toluene, xylene, DMSO, and t-amyl alcohol, and is more preferably toluene. Aqueous solvents cannot be used because moisture inhibits the reaction.
Preferably, the organic solvent is mixed with 11-piperazinyldibenzo [ b, f ]][1,4]Sulphur nitrogen
In a mass ratio of8-10: 1, more preferably 10: 1.
further, the post-treatment is as follows: cooling the reaction liquid to room temperature, evaporating the solvent under reduced pressure, adding ethyl acetate for dissolving, washing with water, drying with anhydrous magnesium sulfate, filtering, evaporating the ethyl acetate from the filtrate under reduced pressure, purifying by using a rapid preparative liquid chromatograph, eluting by using a mixed solution of ethyl acetate and petroleum ether in a volume ratio of 2-20: 100 as an eluent, collecting the eluent containing the target product, and distilling under reduced pressure to obtain quetiapine.
Compared with the prior art, the invention has the beneficial effects that:
11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl catalyzed by ruthenium and using diethylene glycol as a starting material]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
The water is the only byproduct in the preparation process, so that the use of a plurality of toxic halogenating reagents is avoided, the atom utilization rate of the reaction is improved, and the green synthesis of the quetiapine is successfully realized.
(IV) detailed description of the preferred embodiments
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. Numerous technical details are set forth in order to provide a thorough understanding of the present invention, including some technical terms used herein. However, the technical solution claimed in the present application can be implemented without these technical details and some changes and modifications to the following embodiments.
The formula for calculating the yield (irrespective of purity) in the following examples is:
Y＝(myield of the product/MProduct of)/NRaw materials
mYield of the productMass of product containing impurities, MProduct ofIs the relative molecular mass of the target product, NRaw materialsThe amount of material that is the reactant for which the amount of material is smaller.
The flash preparative liquid chromatograph used in the following examples was a Biotage purification apparatus, model Biotage Isolera One.
Example 1:
to a 10mL pressure tube was added 1mL of toluene, 0.089g (0.3mmol) of 11-piperazinyldibenzo [ b, f ]][1,4]Sulphur nitrogen
0.106g (1.0mmol) of diethylene glycol, 2.30mg (1 mol%) of bis (triphenylphosphine) carbonylacetonitrile dichlororuthenium and stirring. Heating to 140 ℃, reacting for 5h, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the solvent, adding 2mL of ethyl acetate into the residue, washing with water for 2 times, adding anhydrous magnesium sulfate for drying, filtering, distilling the filtrate under reduced pressure to remove the ethyl acetate, rapidly preparing liquid chromatograph for purification (the volume ratio of the ethyl acetate to the petroleum ether is 5:100), collecting eluent containing the target product, and distilling under reduced pressure to remove the eluent to obtain the 11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
Oil 0.107 g. Yield: 93.0%, HPLC purity: 96.85 percent.1H NMR(500MHz,CDCl3)δ7.51(d,J＝7.5Hz,1H),7.39(dd,J＝7.7,1.4Hz,1H),7.37–3.28(m,3H),7.18(td,J＝8.0,1.5Hz,1H),7.08(dd,J＝8.0,1.3Hz,1H),6.89(td,J＝7.6,1.4Hz,1H),3.78–3.74(m,2H),3.73–3.69(m,2H),3.69–3.65(m,3H),3.64–3.58(m,5H),2.71–2.62(m,3H),2.61–2.51(m,2H).13C NMR(126MHz,CDCl3)δ160.60,148.81,139.89,134.02,132.15,132.13,130.79,129.08,128.93,128.27,127.94,125.26,122.83,72.41,72.33,67.43,61.85(2C),61.62,57.93(2C).HRMS(ES+)m/z calcd for C21H25N3O2S([M+H]+)384.1740,found 384.1745.
Example 2:
to a 10mL pressure tube was added 0.8mL of xylene, 0.089g (0.3mmol) of 11-piperazinyldibenzo [ b, f ]][1,4]Sulphur nitrogen
0.032g (0.3mmol) of diethylene glycol, 0.51mg (0.2 mol%) of bis (triphenylphosphine) carbonyl dichloride monohydrateAnd (4) dissolving ruthenium and stirring. Heating to 160 ℃, reacting for 10h, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the solvent, adding 2mL of ethyl acetate into the residue, washing with water for 2 times, adding anhydrous magnesium sulfate for drying, filtering, distilling the filtrate under reduced pressure to remove the ethyl acetate, rapidly preparing liquid chromatograph for purification, collecting eluent containing the target product, and removing the eluent by reduced pressure distillation to obtain the 11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
Oil 0.104 g. Yield: 90.4%, HPLC purity: 97.75 percent. HRMS (ES +) m/z calcd for C21H25N3O2S([M+H]+)384.1740,found 384.1745.
Example 3:
to a 10mL pressure tube was added 1mL of DMSO, 0.089g (0.3mmol) of 11-piperazinyldibenzo [ b, f ]][1,4]Sulphur nitrogen
0.177g (1.7mmol) of diethylene glycol, 2.30mg (1 mol%) of bis (triphenylphosphine) carbonylacetonitrile dichlororuthenium and stirring. Heating to 140 ℃, reacting for 3h, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the solvent, adding 2mL of ethyl acetate into the residue, washing with water for 2 times, adding anhydrous magnesium sulfate for drying, filtering, distilling the filtrate under reduced pressure to remove the ethyl acetate, rapidly preparing liquid chromatograph for purification, collecting eluent containing the target product, and removing the eluent by reduced pressure distillation to obtain the 11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
Oil 0.014 g. Yield: 12.1%, HPLC purity: 98.05 percent. HRMS (ES +) m/z calcd for C21H25N3O2S([M+H]+)384.1740,found 384.1745.
Example 4:
to a 10mL pressure tube was added 1mL t-amyl alcohol, 0.089g (0.3mmol) of 11-piperazinyldibenzo [ b, f ]][1,4]Sulphur nitrogen
0.106g (1.0mmol) of diethylene glycol and 12.7mg (3 mol%) of tetrakis (triphenylphosphine) ruthenium dichloride are stirred. Heating to 150 ℃, reacting for 5h, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the solvent, adding 2mL of ethyl acetate into the residue, washing with water for 2 times, adding anhydrous magnesium sulfate for drying, filtering, distilling the filtrate under reduced pressure to remove the ethyl acetate, rapidly preparing liquid chromatograph for purification, collecting eluent containing the target product, and removing the eluent by reduced pressure distillation to obtain the 11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
Oil 0.09 g. Yield: 8.1%, HPLC purity: 98.05 percent. HRMS (ES +) m/z calcd for C21H25N3O2S([M+H]+)384.1740,found 384.1745.
Example 5:
to a 10mL pressure tube was added 1mL t-amyl alcohol, 0.089g (0.3mmol) of 11-piperazinyldibenzo [ b, f ]][1,4]Sulphur nitrogen
0.106g (1.0mmol) of diethylene glycol, 2.30mg (1 mol%) of bis (triphenylphosphine) carbonylacetonitrile dichlororuthenium and stirring. Heating to 120 ℃, reacting for 5h, cooling to room temperature after the reaction is finished, distilling under reduced pressure to remove the solvent, adding 2mL of ethyl acetate into the residue, washing with water for 2 times, adding anhydrous magnesium sulfate for drying, filtering, distilling the filtrate under reduced pressure to remove the ethyl acetate, rapidly preparing liquid chromatograph for purification, collecting eluent containing the target product, and removing the eluent by reduced pressure distillation to obtain the 11- [4- [2- (2-hydroxyethoxy) ethyl-1-piperazinyl]]-dibenzo [ b, f ]][1,4]Sulphur nitrogen
0.052g of oil. Yield: 45.5%, HPLC purity: 99.00 percent. HRMS (ES +) m/z calcd for C21H25N3O2S([M+H]+)384.1740,found 384.1745.
Claims (10)
1. A preparation method of quetiapine is characterized by comprising the following steps:
with 11-piperazinyl dibenzo [ b, f][1,4]Sulphur nitrogen
Reacting with diethylene glycol serving as a raw material in a ruthenium catalyst and an organic solvent at 120-160 ℃ for 3-10 h, and carrying out aftertreatment on the obtained reaction liquid to obtain quetiapine; the ruthenium catalyst, diethylene glycol and 11-piperazinyl dibenzo [ b, f ]][1,4]Sulphur nitrogen
The amount ratio of the substances (A) is 0.02 to 0.05: 1-5: 1; the ruthenium catalyst is bis (triphenylphosphine) carbonyl acetonitrile ruthenium dichloride, bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate or tetrakis (triphenylphosphine) ruthenium dichloride.
2. A process for the preparation of quetiapine as claimed in claim 1 wherein: the organic solvent is any one of toluene, xylene, DMSO and tert-amyl alcohol.
3. A process for the preparation of quetiapine as claimed in claim 2 wherein: the organic solvent is toluene.
4. A process for the preparation of quetiapine as claimed in claim 1 wherein: the organic solvent is mixed with 11-piperazinyl dibenzo [ b, f][1,4]Sulphur nitrogen
The mass ratio of (A) to (B) is 8-10: 1.
5. a process for the preparation of quetiapine as claimed in claim 4 wherein: the organic solvent is mixed with 11-piperazinyl dibenzo [ b, f][1,4]Sulphur nitrogen
The mass ratio of (A) to (B) is 10: 1.
6. a process for the preparation of quetiapine as claimed in claim 1 wherein: the ruthenium catalyst is bis (triphenylphosphine) carbonyl acetonitrile and ruthenium dichloride.
7. A process for the preparation of quetiapine as claimed in claim 1 wherein: the reaction condition is that the reaction is carried out for 5 hours at 140 ℃.
8. A process for the preparation of quetiapine as claimed in claim 1 wherein: the ruthenium catalyst, diethylene glycol and 11-piperazinyl dibenzo [ b, f ]][1,4]Sulphur nitrogen
The ratio of the amounts of substances (a) to (b) is 0.03: 3: 1.
9. a process for the preparation of quetiapine as claimed in claim 1 wherein the post-treatment is: cooling the reaction liquid to room temperature, evaporating the solvent under reduced pressure, adding ethyl acetate for dissolving, washing with water, drying with anhydrous magnesium sulfate, filtering, evaporating the ethyl acetate from the filtrate under reduced pressure, purifying by using a rapid preparative liquid chromatograph, eluting by using a mixed solution of ethyl acetate and petroleum ether in a volume ratio of 2-20: 100 as an eluent, collecting the eluent containing the target product, and distilling under reduced pressure to obtain quetiapine.
10. A process for the preparation of quetiapine as claimed in claim 9 wherein: the eluent is a mixed solution of ethyl acetate and petroleum ether with the volume ratio of 10: 100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110308560.3A CN112939892B (en) | 2021-03-23 | 2021-03-23 | Preparation method of quetiapine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110308560.3A CN112939892B (en) | 2021-03-23 | 2021-03-23 | Preparation method of quetiapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112939892A true CN112939892A (en) | 2021-06-11 |
| CN112939892B CN112939892B (en) | 2022-10-04 |
Family
ID=76227589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110308560.3A Active CN112939892B (en) | 2021-03-23 | 2021-03-23 | Preparation method of quetiapine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112939892B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08311029A (en) * | 1995-03-10 | 1996-11-26 | Nissan Chem Ind Ltd | Alkylation of heteroaromatic amine |
| CN101619047A (en) * | 2009-08-17 | 2010-01-06 | 浙江苏泊尔制药有限公司 | Preparation process of quetiadine hemifumarate |
| CN102491949A (en) * | 2011-12-16 | 2012-06-13 | 南京理工大学 | Method for synthesizing 2-(N-alkyl) aminopyrimidine derivatives by means of N-alkylation |
| US20160009632A1 (en) * | 2013-03-04 | 2016-01-14 | Takasago International Corporation | Method for alkylation of amines |
| CN105859653A (en) * | 2016-04-29 | 2016-08-17 | 嘉兴学院 | Quetiapine synthesizing method |
| CN110475783A (en) * | 2017-03-31 | 2019-11-19 | 高砂香料工业株式会社 | Cationic ruthenium complex and preparation method thereof with and application thereof |
-
2021
- 2021-03-23 CN CN202110308560.3A patent/CN112939892B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08311029A (en) * | 1995-03-10 | 1996-11-26 | Nissan Chem Ind Ltd | Alkylation of heteroaromatic amine |
| CN101619047A (en) * | 2009-08-17 | 2010-01-06 | 浙江苏泊尔制药有限公司 | Preparation process of quetiadine hemifumarate |
| CN102491949A (en) * | 2011-12-16 | 2012-06-13 | 南京理工大学 | Method for synthesizing 2-(N-alkyl) aminopyrimidine derivatives by means of N-alkylation |
| US20160009632A1 (en) * | 2013-03-04 | 2016-01-14 | Takasago International Corporation | Method for alkylation of amines |
| CN105859653A (en) * | 2016-04-29 | 2016-08-17 | 嘉兴学院 | Quetiapine synthesizing method |
| CN110475783A (en) * | 2017-03-31 | 2019-11-19 | 高砂香料工业株式会社 | Cationic ruthenium complex and preparation method thereof with and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| BENJAMIN APPIAGYEI ET AL.: "Electroactivated alkylation of amines with alcohols via both direct and indirect borrowing hydrogen mechanisms", 《GREEN CHEM.》 * |
| FEDERICO V. ROSSI ET AL.: "Synthesis of PEG-Functionalized Amines Using Ruthenium-Catalyzed Hydrogen Borrowing", 《ORG. LETT.》 * |
| R. GRIG ET AL.: "Transition Metal-catalysed N -Alkylation of Amines by Alcohols", 《J.C.S. CHEM. COMM》 * |
| YUSHI NAKAMURA EY AL.: "Ruthenium-catalyzed hydroxyethylation of cyclic amines with ethylene glycol", 《HETEROCYCLES》 * |
| 吴慧 等: "后过渡金属催化醇对胺的N-烷基化反应研究进展", 《有机化学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112939892B (en) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106831550A (en) | A kind of optical activity two（It is miscellaneous）Aryl methyl alcohol and its method of asymmetric synthesis | |
| CN112939892B (en) | Preparation method of quetiapine | |
| CN103183673A (en) | Synthesizing method of (S,S)-2,8-diazabicyclo[4.3.0]nonane | |
| CN108947800B (en) | Synthesis method of (1S) -4, 5-dimethoxy-1- (carbonylaminomethyl) benzocyclobutane | |
| CN111925317B (en) | Ropivacaine hydrochloride impurity and preparation method thereof | |
| JP6676146B2 (en) | Novel production method of chromanol derivative | |
| CN101500981A (en) | Process for preparing quaternary alkylammonium halides | |
| CN111747926B (en) | Improved synthetic process method of topiramate free base | |
| CN110698335A (en) | Synthesis method of terbutaline intermediate | |
| CN110294708B (en) | Preparation method of trifluoroethylselenophenanthridine and 3, 4-dihydroisoquinoline derivatives | |
| CN102212040B (en) | Novel preparation method for chiral 2-hydroxymethyl morpholine compounds | |
| CN111440198A (en) | 1,10 a-dihydro-2H-pyridine [1,2-d ] [1,4] sulfur nitrogen compound and preparation method thereof | |
| CN111732552A (en) | Method for synthesizing 1, 3-oxazole-2-thioketone by palladium catalysis | |
| CN113563255A (en) | Preparation method of Rifloxacin intermediate | |
| CN114835646B (en) | Imidazole trifluoro methylthio reagent and synthesis application thereof | |
| CN118043313A (en) | Process for producing alkyl furan carboxylic acid ester | |
| CN113461615B (en) | Preparation method of 4-fluoro-1H-pyrazole | |
| CN114605494B (en) | Argatroban and preparation method of intermediate thereof | |
| CN114957106B (en) | Mobile phase automatic synthesis method of drug pirfenidone | |
| CN112521289B (en) | Oxaallylamine compound and preparation method and application thereof | |
| CN114685369B (en) | Method for preparing 1-methyl-1, 2,3, 4-tetrahydroisoquinoline by utilizing ionic liquid | |
| CN112625015B (en) | Preparation method of 2- (1, 3-dihydro-2-isobenzofuran) -1-acetophenone compound | |
| CN106278846A (en) | A kind of method of synthesis 3,5 bis trifluoromethyl 1-Phenylethanone .s | |
| CN105622544A (en) | Synthetic method of N-sulfonyl-3,4-dihydro-2H-1,4-thiazine | |
| CN117865927A (en) | Preparation method of landiolol hydrochloride and intermediate thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |